CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 120 enrolled
Drug / intervention
chemotherapy group +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03243825
NCT03243825N/ACompleted
CompareCT.gov

Comparative Study of Neoadjuvant Chemo/Brachytherapy and Chemotherapy Alone Before Radical Hysterectomy in Stage Ib2-IIa2 Cervical Cancer

Chinese Academy of Medical Sciences·interventional·Posted Aug 9, 2017·Updated Aug 9, 2017

In Brief

A clinical study evaluating combination group and chemotherapy group for Cervical Cancer. Completed, enrolled 120 participants across 1 site.

Detailed Summary

For stage Ib2-IIa2 cervical cancer patients, neoadjuvant therapy followed by radical hysterectomy and pelvic lymphadenectomy is one of the managements. Post-operative concurrent chemo-radiotherapy is necessary if the patients have high-risk factors, including positive surgical margin, parametrium and pelvic nodes. Our previous retrospective study showed that combination of neoadjuvant chemotherapy and brachytherapy reduced the proportion of post-operative concurrent chemo-radiotherapy compared to neoadjuvant chemotherapy alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 9, 2017
Enrollment StartNov 1, 2012
Primary CompletionJun 1, 2015
Study CompletionJul 1, 2015
TodayJul 1, 2026
Enrollment to primary: 2.6 yearsPosted 8.9 years ago

Interventions

combination groupradiation

chemotherapy (paclitaxel/cisplatinum) and brachytherapy

chemotherapy groupdrug

chemotherapy: (paclitaxel/cisplatinum)